What is an atypical teratoid/rhabdoid tumour?
An atypical teratoid/rhabdoid tumour (AT/RT or ATRT) is a rare, fast-growing cancer of the brain or spinal cord. It mainly affects babies and children aged 3 years and younger, although it can occasionally occur in older children and adults.
The name comes from the way the tumour looks under the microscope. It contains “rhabdoid” cells, which resemble muscle cells, mixed with other cell types, so it can look like several different tumours at once (“atypical teratoid”).
The WHO Classification of Tumours of the Central Nervous System, 5th edition (2021) groups AT/RT with the embryonal tumours, the cancers that arise from very immature cells. It is a CNS WHO grade 4 tumour, the most aggressive grade.
AT/RT is defined by the loss of a single gene, SMARCB1 (also called INI1) or, much less often, SMARCA4. Testing for this loss has made it possible to tell AT/RT apart from other childhood brain tumours. Before the 1990s, many cases were diagnosed as medulloblastoma or primitive neuroectodermal tumour.
1. How common is it?
| Feature | Details |
|---|---|
| Overall | Rare; exact numbers are hard to measure because the tumour has been recognised only since the 1990s |
| Young children | About 10% of brain tumours in children aged 3 years and younger in two North American studies |
| Peak age | First 2 years of life; median age about 18 months in children without an inherited gene change |
| Older children and adults | Less common; in one North American registry, 29% of patients were older than 3 years |
| Children with an inherited gene change | Usually diagnosed earlier, at a median age of about 5 months in one study |
| Location | About half arise in the posterior fossa (cerebellum and brainstem); the rest mainly in the cerebral hemispheres; rarely in the spinal cord |
AT/RT is not infectious. It cannot be caused by anything the parents did or did not do during pregnancy.
2. Causes
AT/RT is caused by the loss of both working copies of the SMARCB1 gene on chromosome 22, or, in a small number of cases, of the SMARCA4 gene on chromosome 19. Both genes make parts of the SWI/SNF complex, a group of proteins that opens and closes DNA so the right genes are switched on at the right time.
When SMARCB1 or SMARCA4 is lost, immature brain cells cannot develop normally and grow out of control. Apart from this single change, AT/RT has very few other gene mutations, which is unusual for such an aggressive cancer.
Rhabdoid tumour predisposition syndrome
Up to about a third of children with AT/RT are born with a faulty copy of SMARCB1 (or SMARCA4) in every cell. This is called rhabdoid tumour predisposition syndrome (RTPS).
| Feature | Details |
|---|---|
| RTPS type 1 | Caused by a germline SMARCB1 change; the more common type |
| RTPS type 2 | Caused by a germline SMARCA4 change; rare; may also cause a type of ovarian cancer in young women |
| Typical signs | Very young age at diagnosis, tumours in more than one place, a rhabdoid tumour in the kidney or soft tissue as well as the brain, or affected brothers or sisters |
| Inheritance | Can be passed on in an autosomal dominant way, but some parents who carry the change never develop a tumour; many cases are new changes |
| What it means | Genetic testing and counselling are offered to every family; carriers may be offered regular screening scans |
Molecular groups
Doctors now divide AT/RT into three main molecular groups using DNA methylation testing of the tumour. These groups help explain why outcomes differ and may guide treatment in the future.
| Group | Share of cases | Typical features |
|---|---|---|
| ATRT-TYR | About one third | Mostly in the posterior fossa; mostly babies under 1 year; often a better outlook |
| ATRT-SHH | About 40% | Above or below the tentorium; most under 2 years, but about a third aged 2-5 |
| ATRT-MYC | About a quarter | Usually in the cerebral hemispheres; the most common group in children aged 6 and older |
Tumours driven by SMARCA4 loss form a further, distinct group.
3. How does it look?
3.1 On scans
| Feature | Typical appearance on MRI or CT |
|---|---|
| Size | Often large at diagnosis, because it grows quickly |
| Texture | Mixed solid and cystic parts, sometimes with bleeding or calcium deposits |
| Contrast | Patchy or ring-like enhancement after contrast dye |
| Diffusion imaging | Bright, because the tumour is tightly packed with cells |
| Fluid spaces | Enlarged ventricles (hydrocephalus) when the tumour blocks the flow of cerebrospinal fluid |
| Spine MRI | May show tumour deposits on the lining of the spinal cord (leptomeningeal spread) |
AT/RT cannot be reliably told apart from other malignant brain tumours, such as medulloblastoma, on scans alone. Surgery or a biopsy is always needed for the diagnosis.
3.2 During surgery
The tumour is usually soft and fleshy, with areas of bleeding and dead tissue. It often grows into the surrounding brain without a clear border, which can make complete removal difficult.
3.3 Under the microscope
| Feature | Description |
|---|---|
| Rhabdoid cells | Medium to large cells with the nucleus pushed to one side, a prominent nucleolus and pink cytoplasm; not present in every tumour |
| Mixed areas | Small round “blue” primitive cells, together with epithelial, mesenchymal or glial-like areas |
| Growth rate | Very high; the Ki-67 (MIB-1) index is often 50-100% |
| Key stain | Loss of SMARCB1 (INI1) protein in the tumour cell nuclei, while normal cells such as blood vessel cells keep it; or, rarely, loss of SMARCA4 (BRG1) |
| Other stains | Often positive for vimentin, epithelial membrane antigen (EMA) and smooth muscle actin |
A brain tumour that looks like AT/RT but has no SMARCB1 or SMARCA4 change is called a CNS embryonal tumour with rhabdoid features instead.
4. Symptoms
AT/RT grows quickly, so symptoms often develop over days to weeks. They depend on where the tumour is and on the child’s age, and babies cannot describe what they feel.
| Cause | Common symptoms |
|---|---|
| Raised pressure in the head (hydrocephalus) | Headaches, especially in the early morning; vomiting, often on waking; sleepiness or listlessness; irritability |
| Babies with open skull bones | A rapidly growing head, a bulging soft spot (fontanelle), and eyes that look downwards (“sunsetting”) |
| Posterior fossa tumour | Unsteady walking or loss of balance (ataxia), clumsiness, loss of skills such as sitting or walking |
| Cranial nerve involvement | Squint or double vision, a drooping face, swallowing problems, head tilt |
| Tumour in the cerebral hemispheres | Seizures, weakness on one side of the body, changes in behaviour or alertness |
| Spinal tumour or spinal spread | Back pain, weakness of the legs, changes in bladder or bowel control |
| General | Poor feeding, weight loss, developmental regression |
When to seek urgent medical help
- Repeated morning vomiting, especially with headache or sleepiness.
- A baby whose head is growing quickly or whose fontanelle is bulging.
- A child who loses skills such as sitting, walking or talking.
- A first seizure, new squint or sudden weakness.
5. Diagnosis
| Test | Purpose |
|---|---|
| MRI of the brain and whole spine | Shows the tumour and any spread along the brain and spinal cord |
| Lumbar puncture | Checks the spinal fluid for tumour cells, when safe |
| Surgery or biopsy | Removes as much tumour as is safe and provides tissue |
| SMARCB1 (INI1) and SMARCA4 stains | Confirm AT/RT |
| DNA methylation profiling | Confirms the diagnosis and the molecular group |
| Blood test for germline SMARCB1 or SMARCA4 changes | Looks for rhabdoid tumour predisposition syndrome |
| Kidney ultrasound or whole-body MRI | Looks for a second rhabdoid tumour outside the brain |
| Hearing, heart, kidney and blood tests | Baseline checks before intensive chemotherapy |
There is no formal staging system for AT/RT. For treatment, doctors note whether the tumour is localised or has spread (metastatic), how much was removed and the child’s age.
6. Treatment
There is no single proven standard treatment for AT/RT. Most children receive intensive multimodal therapy: surgery, chemotherapy (often including high-dose chemotherapy with stem cell rescue) and radiotherapy where possible. Treatment should take place in a specialist children’s neuro-oncology centre, ideally within a clinical trial or registry.
6.1 Main treatment options
| Treatment | What it involves | Purpose | Main side effects |
|---|---|---|---|
| Surgery | Neurosurgery to remove as much tumour as safely possible; a shunt or drain if fluid builds up | Relieves pressure and provides tissue; complete removal is linked with better survival | Risks of bleeding, infection and new neurological problems; posterior fossa syndrome (loss of speech and mood changes) after some cerebellar operations |
| Induction chemotherapy | Several cycles of combination chemotherapy into a vein | Shrinks remaining tumour and treats spread | Low blood counts, infections, nausea, hair loss, hearing and kidney damage (cisplatin) |
| High-dose chemotherapy with stem cell rescue | Very strong chemotherapy (for example carboplatin and thiotepa), followed by return of the child’s own stem cells collected earlier | Kills remaining cancer cells | Severe low blood counts, serious infections, mouth sores, liver problems; requires long hospital stays |
| Intrathecal chemotherapy | Chemotherapy into the spinal fluid, by lumbar puncture or a reservoir under the scalp | Treats or prevents spread in the fluid spaces; used in some regimens | Headache, infection risk, rarely brain irritation |
| Focal radiotherapy | Precise radiotherapy to the tumour area, often with proton therapy or 3D conformal photons | Reduces the risk of the tumour regrowing locally | Effects on learning, growth and hormones, especially in very young children |
| Craniospinal radiotherapy | Radiotherapy to the whole brain and spine | For spread through the nervous system, usually in older children | Larger effects on learning, growth, hormones and hearing |
6.2 Treatment regimens
- Children’s Oncology Group ACNS0333. After surgery, children received 2 cycles of induction chemotherapy (including methotrexate, cyclophosphamide, cisplatin and etoposide), followed by 3 cycles of high-dose carboplatin and thiotepa with stem cell rescue. Focal radiotherapy was given after induction or after high-dose chemotherapy, depending on age and tumour site.
- Dana-Farber regimen. This was based on a rhabdomyosarcoma protocol (IRS-III) and used chemotherapy into the spinal fluid together with focal or craniospinal radiotherapy.
- European Rhabdoid Registry (EU-RHAB). This registry recommends multi-agent chemotherapy, with high-dose chemotherapy or maintenance therapy in selected children, and radiotherapy depending on age.
6.3 Radiotherapy in very young children
Radiotherapy is important in AT/RT, and registry data link it with better survival. However, it can harm the developing brain, so doctors balance its benefits against long-term effects.
Focal radiotherapy is now often given even to children younger than 3 years. Radiotherapy to the whole brain and spine is usually reserved for older children or those with spread.
6.4 Relapse and new treatments
| Approach | Details |
|---|---|
| Further surgery, chemotherapy or radiotherapy | Depends on the site of relapse and previous treatment |
| EZH2 inhibitors (for example tazemetostat) | SMARCB1 loss makes tumour cells depend on a protein called EZH2; responses have been seen in other SMARCB1-deficient cancers, and trials in children are under way |
| Other targeted drugs and immunotherapy | Being tested in early clinical trials |
| Palliative care | Control of symptoms and support for the family, alongside or instead of further treatment |
Most relapses happen within the first 2 years after diagnosis. In ACNS0333, 91% of relapses occurred within 2 years of enrolment.
7. Outlook
AT/RT remains one of the most serious childhood brain tumours. Older studies reported an average survival of only about a year, but intensive multimodal treatment has improved results.
| Study or group | Reported outcome |
|---|---|
| ACNS0333 (65 evaluable children) | 4-year event-free survival 37% and overall survival 43% |
| ACNS0333, children under 36 months | 4-year event-free survival 35%, compared with 6.4% in a historical group treated with chemotherapy alone |
| ACNS0333, children 36 months and older | 4-year event-free survival 48% and overall survival 57% |
| Dana-Farber regimen (prospective study) | 2-year progression-free survival 53% and overall survival 70% |
| EU-RHAB registry (143 children) | 5-year overall survival about 35% for the whole group |
| EU-RHAB: age 1 year or older with ATRT-TYR | 5-year overall survival about 71% |
| EU-RHAB: under 1 year with ATRT-SHH or ATRT-MYC | Very poor survival |
Factors linked with a poorer outlook
- Age under 1 year.
- Spread of the tumour at diagnosis.
- Incomplete removal of the tumour.
- An inherited SMARCB1 or SMARCA4 change.
- Certain molecular groups (non-TYR tumours in infants).
Treatment itself carries risks. In ACNS0333, 4 children (6%) died from treatment-related complications such as infection.
These figures describe groups of children and cannot predict what will happen to an individual child. Your child’s team can explain what the results mean in your situation.
8. Living with AT/RT
Long-term effects
| Area | Possible effects |
|---|---|
| Learning and memory | Problems with attention, processing speed and school progress, especially after radiotherapy at a young age |
| Hormones and growth | Short stature, thyroid problems, delayed or early puberty |
| Hearing | High-frequency hearing loss after cisplatin and carboplatin; hearing aids may be needed |
| Movement and balance | Weakness or poor coordination after surgery |
| Other organs | Kidney, heart or fertility problems after chemotherapy |
| Second cancers | A small increased risk after radiotherapy and chemotherapy, and in children with RTPS |
Support and follow-up
- Regular MRI scans of the brain and spine are done for several years, most often in the first 2 years.
- Many children need physiotherapy, occupational therapy and speech and language therapy during and after treatment.
- A neuropsychology assessment helps plan support at nursery and school.
- Children with RTPS and their relatives who carry the gene change may be offered screening scans.
- Palliative care teams help with symptoms and family support at any stage, not only at the end of life.
- Families can find support through children’s cancer charities and brain tumour organisations, such as the Children’s Brain Tumor Foundation and The Brain Tumour Charity.
9. Frequently asked questions
| Question | Answer |
|---|---|
| Did we cause this? | No. AT/RT is caused by a gene change in the tumour cells, and nothing parents did or did not do causes it |
| Could our other children be affected? | Usually not, but up to a third of children have an inherited gene change. Genetic testing tells the family whether brothers and sisters need checks |
| Why is treatment so intensive? | Because AT/RT grows quickly and often spreads, milder treatment has had poor results |
| Can my baby have radiotherapy? | Focal radiotherapy, often with protons, is increasingly used even in young children; the team balances benefits and long-term effects |
| Can AT/RT be cured? | Yes, some children are cured, especially those whose tumour is completely removed and who complete intensive treatment |
Resources
- Louis, D.N. et al. (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
- Biegel, J.A. et al. (1999) ‘Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors’, Cancer Research, 59(1), pp. 74-79.
- Hasselblatt, M. et al. (2011) ‘Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression’, American Journal of Surgical Pathology, 35(6), pp. 933-935.
- Hasselblatt, M. et al. (2014) ‘SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis’, Acta Neuropathologica, 128(3), pp. 453-456.
- Johann, P.D. et al. (2016) ‘Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes’, Cancer Cell, 29(3), pp. 379-393.
- Ho, B. et al. (2020) ‘Molecular subgrouping of atypical teratoid/rhabdoid tumors – a reinvestigation and current consensus’, Neuro-Oncology, 22(5), pp. 613-624.
- Holdhof, D. et al. (2021) ‘Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases’, Acta Neuropathologica, 141(2), pp. 291-301.
- Fruhwald, M.C. et al. (2016) ‘Atypical teratoid/rhabdoid tumors – current concepts, advances in biology, and potential future therapies’, Neuro-Oncology, 18(6), pp. 764-778.
- Fruhwald, M.C. et al. (2020) ‘Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors’, Neuro-Oncology, 22(7), pp. 1006-1017.
- Chi, S.N. et al. (2009) ‘Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor’, Journal of Clinical Oncology, 27(3), pp. 385-389.
- Reddy, A.T. et al. (2020) ‘Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the Children’s Oncology Group trial ACNS0333’, Journal of Clinical Oncology, 38(11), pp. 1175-1185.
- Upadhyaya, S.A. et al. (2021) ‘Relevance of molecular groups in children with newly diagnosed atypical teratoid rhabdoid tumor: results from prospective St. Jude multi-institutional trials’, Clinical Cancer Research, 27(10), pp. 2879-2889.
- National Cancer Institute (2026) Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-cns-atrt-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Childhood Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/brain/patient/child-cns-atrt-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.